Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review

被引:2
作者
Ismail, Fatme Seval [1 ]
Gallus, Marco [2 ,3 ]
Meuth, Sven G. [4 ,5 ]
Okada, Hideho [2 ,6 ,7 ]
Hartung, Hans-Peter [4 ,5 ,8 ,9 ]
Melzer, Nico [4 ,5 ]
机构
[1] Knappschaftskrankenhaus Recklinghausen, Dept Neurol, Klinikum Vest, Dorstener Str 151, D-45657 Recklinghausen, Germany
[2] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[3] Univ Hosp Muenster, Dept Neurosurg, Munster, Germany
[4] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany
[5] Heinrich Heine Univ Dusseldorf, Univ Hosp, Dusseldorf, Germany
[6] Parker Inst Canc Immunotherapy, San Francisco, CA USA
[7] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[8] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia
[9] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic
基金
美国国家卫生研究院;
关键词
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NEUROMYELITIS-OPTICA; CART CELLS; GLIOBLASTOMA; CANCER; MULTICENTER; EFFICACY; IMMUNITY; TYPE-16; MARKER;
D O I
10.1001/jamaneurol.2024.3818
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Importance Advancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors (CARs). This is promising not only in cancer treatment but also in addressing a spectrum of other conditions. This review provides a comprehensive overview of the current approaches and future potential of CAR T-cell therapy in the field of neurology, particularly for primary brain tumors and autoimmune neurological disorders. Observations: CAR T-cell therapy for glioblastoma is promising; however, first-in-human trials did not yield significant success or showed only limited success in a subset of patients. To date, the efficacy of CAR T-cell therapies has been demonstrated in animal models of multiple sclerosis, but larger human studies to corroborate the efficacy remain pending. CAR T cells showed efficacy in treatment of patients with relapsed or refractory aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorders. Further studies with larger patient populations are needed to confirm these results. Success was reported also for treatment of cases with generalized myasthenia gravis using CAR T cells. Chimeric autoantibody receptor T cells, representing a modified form of CAR T cells directed against autoreactive B cells secreting autoantibodies, were used to selectively target autoreactive anti-N-methyl-d-aspartate B cells under in vitro and in vivo conditions, providing the basis for human studies and application to other types of autoimmune encephalitis associated with neuronal or glial antibodies. Conclusions and Relevance: CAR T cells herald a new era in the therapeutic landscape of neurological disorders. While their application in solid tumors, such as glioblastoma, has not universally yielded robust success, emerging innovative strategies show promise, and there is optimism for their effectiveness in certain autoimmune neurological disorders.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 96 条
  • [1] HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
    Ahmed, Nabil
    Brawley, Vita
    Hegde, Meenakshi
    Bielamowicz, Kevin
    Kalra, Mamta
    Landi, Daniel
    Robertson, Catherine
    Gray, Tara L.
    Diouf, Oumar
    Wakefield, Amanda
    Ghazi, Alexia
    Gerken, Claudia
    Yi, Zhongzhen
    Ashoori, Aidin
    Wu, Meng-Fen
    Liu, Hao
    Rooney, Cliona
    Dotti, Gianpietro
    Gee, Adrian
    Su, Jack
    Kew, Yvonne
    Baskin, David
    Zhang, Yi Jonathan
    New, Pamela
    Grilley, Bambi
    Stojakovic, Milica
    Hicks, John
    Powell, Suzanne Z.
    Brenner, Malcolm K.
    Heslop, Helen E.
    Grossman, Robert
    Wels, Winfried S.
    Gottschalk, Stephen
    [J]. JAMA ONCOLOGY, 2017, 3 (08) : 1094 - 1101
  • [2] Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma
    Ahrendsen, Jared T.
    Sehgal, Kartik
    Sarangi, Sasmit
    Uhlmann, Erik J.
    Varma, Hemant
    Arnason, Jon
    Avigan, David
    [J]. JOURNAL OF HEMATOLOGY, 2021, 10 (05) : 212 - 216
  • [3] Updates in prognostic markers for gliomas
    Aquilanti, Elisa
    Miller, Julie
    Santagata, Sandro
    Cahill, Daniel P.
    Brastianos, Priscilla K.
    [J]. NEURO-ONCOLOGY, 2018, 20 : 17 - 26
  • [4] The immunology of multiple sclerosis
    Attfield, Kathrine E.
    Jensen, Lise Torp
    Kaufmann, Max
    Friese, Manuel A.
    Fugger, Lars
    [J]. NATURE REVIEWS IMMUNOLOGY, 2022, 22 (12) : 734 - 750
  • [5] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [6] Multiple Sclerosis: Mechanisms and Immunotherapy
    Baecher-Allan, Clare
    Kaskow, Belinda J.
    Weiner, Howard L.
    [J]. NEURON, 2018, 97 (04) : 742 - 768
  • [7] Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
    Bagley, Stephen J.
    Logun, Meghan
    Fraietta, Joseph A.
    Wang, Xin
    Desai, Arati S.
    Bagley, Linda J.
    Nabavizadeh, Ali
    Jarocha, Danuta
    Martins, Rene
    Maloney, Eileen
    Lledo, Lester
    Stein, Carly
    Marshall, Amy
    Leskowitz, Rachel
    Jadlowsky, Julie K.
    Christensen, Shannon
    Oner, Bike Su
    Plesa, Gabriela
    Brennan, Andrea
    Gonzalez, Vanessa
    Chen, Fang
    Sun, Yusha
    Gladney, Whitney
    Barrett, David
    Nasrallah, MacLean P.
    Hwang, Wei-Ting
    Ming, Guo-Li
    Song, Hongjun
    Siegel, Donald L.
    June, Carl H.
    Hexner, Elizabeth O.
    Binder, Zev A.
    O'Rourke, Donald M.
    [J]. NATURE MEDICINE, 2024, 30 (05) : 1320 - +
  • [8] CAR T therapy beyond cancer: the evolution of a living drug
    Baker, Daniel J.
    Arany, Zoltan
    Baur, Joseph A.
    Epstein, Jonathan A.
    June, Carl H.
    [J]. NATURE, 2023, 619 (7971) : 707 - 715
  • [9] Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status
    Beecher, Grayson
    Putko, Brendan Nicholas
    Wagner, Amanda Nicole
    Siddiqi, Zaeem Azfer
    [J]. DRUGS, 2019, 79 (04) : 353 - 364
  • [10] Blache U, 2023, RMD OPEN, V9, DOI 10.1136/rmdopen-2022-002907